price may usd
ride recoveri wave
sale perform trend much preview monday
total compani revenu declin right line
forecast yr/yr global sale declin across busi greater
mdt peer mdt also includ month april still
believ concur trough due paus elect surgeri
begin mid-march us key eu region like germani treatment
non-covid patient begin resurrect april
repres nadir monthli basi even despit full extra sell week
expect quarterli sale growth actual worsen somewhat sequenti
although struggl bit mdt statement compar
steep ramp hospit note compani see
off-set sharp rise demand within rtg product categori
notabl respiratori mechan ventil patient monitor puls
oximetri capnographi though collect account
compani refrain provid guidanc given myriad
uncertainti direct commentari encourag manag believ
procedur volum overal top-lin recoveri unfold fairli swiftli
begin steadili improv balanc year
return normal growth trend expect stack growth basi
outlook consist thesi vi -- vi time pace
magnitud recoveri surgeri volum med-tech compani also
project return normal volum calendar versu mdt
fiscal mdt manag push today
confer call acknowledg simpli guess pace
recoveri regard oper profit compani made clear
signific de-lever come quarter opex invest plan
remain unchang despit top-lin pressur compani
expect return more-norm ebit margin level
regard volum corrobor commentari heard
consist past coupl week other includ baxter intuit
zimmer regard recoveri clearli continu unfold china
pandem took hold sever week earlier gener
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
total sale china sale overal reflect declin
februari march modest april manag
remark sale growth trend date current quarter continu
recov improv sequenti past three week may
fulli appreci country-to-countri differ result
variabl recoveri curv geographi trend china likewis
apac market like hong kong south korea clearli bode favor regard
outlook procedur recoveri us eu region
addit highli lever procedur rebound capital-expenditure sale account
modest compani sale also highlight compani
good financi health robust balanc sheet liquid
impend debt matur strong cash gener
continu serv compani well manag unpreced crisi
continu highlight rais dividend today wherea peer tap
capit market dilut sharehold order shore balanc
sheet believ mdt financi strength allow compani continu
gener sharehold valu via prioriti use cash deal clearli
expect repo activ avoid reduc headcount and/or
compens peer forc continu make organ
invest pipelin particular result emerg
pandem stronger competit posit
net-net impact covid mdt dire model
mdt refus provid detail guidanc pressur share
today wish could provid guidanc even
guidanc limit revenu impact op margin
get wors howev use data point us hospit struggl
see revenu wors even though acknowledg
saw impact februari saw halfway march model
revenu declin encourag investor read full note
understand logic margin perspect trough
maximum de-lever occur throughout lessen covid
headwind fade throughout year despit covid speed bump believ
continu gain market share core market product
pipelin acceler organ revenu beyond due mdt
pipelin strong balanc sheet reason multipl shareholder-friendli
capit deploy believ remain core large-cap healthcar
hold modestli lower price target base revis
earn forecast reiter buy rate
major pipelin delay unforeseen most-robust pipelin compani
histori new-product mileston remain central focu investor regard
impact pipelin three categori consid
 complet regulatori file review importantli compani
forese signific delay turnaround time regulatori
submiss alreadi file fda obvious encourag
outlook could certainli subject chang given mani unknown
around new coronaviru potenti resurg
remaind due eas lockdown measur and/or season
miniatur recharg interstim micro
repres key pend approv given axon launch sn
implant late last year meaning share sinc captur
within key categori
 within neuro compani submit fda approv ce
mark januari next-gen db implant call percept
featur mdt proprietari brainsens technolog
enabl person therapi motion disord like parkinson
use electr signal individu brain rather patient
diari current-gen db system reliant
diabet fda approv repres huge mileston
technolog gap versu competitor result
abysm segment perform sever quarter particularli
us compani first expect regulatori approv summer
approv patient use
entitl free softwar upgrad enabl use
adult data us pivot trial forthcom
virtual ada meet june iron covid benefit
diabet divis custom hard time swap
current pump competitor pump henc
crhf next-gen reveal linq implant cardiac monitor
help reviv growth diagnost categori
competitor launch stymi growth past coupl
technolog clinical/pre-clin develop compani
sure see slippag timelin initi enrol
studi product clinic develop
 progress hugo surgic robot remain
central focu given compani biggest pipelin
program ever hope high inroad within robot
surgeri market growth contribut mdt top line
next sever year compani acknowledg pre-clin
softwar test still complet due pandemic-rel
delay thu initi human case previous target
commenc quarter slip updat
timelin unclear point
resurrect renal denerv program enrol
spyral-on trial paus ultim
strategi combin data trial spyral off-
result present coupl month ago pma
file fda approv drug refractori hypertens
 within still-challeng diabet busi manag
acknowledg timelin slippag synergi all-in-on
sensor technolog updat time unclear point
 recent approved/launch key new product gain
fda clearanc number major new product past
month lead pandem obvious result
chang origin commerci strategi launch time
highlight mani time past mani product could
notabl matur market like implant innovation-
driven share captur name game product includ
 micra av prior-gen micra vr limit single-
chamber categori util patient av block
concomit af thu cap address market
bradi patient present howev next-gen micra av
approv januari also util patient av
block normal atrial function thu tripl
address market estim overal patient
popul indic perman pacemak procedur
volum begin recov pacemak implant
amongst higher-prior case hospit backlog micra av
drive continu share captur mdt pacemak
franchis throughout beyond indic call
micra sale growth mid-march north
robust earli uptak av bode favor
pacer busi product fulli commerci next
sever quarter launch reveal linq note
fda review stimul low-voltag busi
linq book
pact admir dcb recent approv avf indic
repres increment market opportun
mostli us bdx lutonix alreadi includ indic
fda label
 cobalt chrome icd/crt-d given continu pressur
endur tachi busi recent year due larg
boston emblem s- encroach tradit side
coupl strong headwind unfavor crt-d
product replac cycl believ launch cobalt
chrome could provid signific much-need boost
devic broadli launch notabl implant repres
medtron first new high-voltag platform seven year
fiscal top-lin perform track model quit
close total revenu come bp forecast largest delta
report result vs forecast gross margin contract
bp y/i manag indic expect see addit bp
sequenti pressur fiscal sg came bp lighter
expect de-lever seem like given plan
continu invest workforc busi develop
pandem therefor expect sequenti op margin contract
bp sharp rebound back start
acknowledg model challeng current environ
help give investor transpar assumpt within model
everi year get extra sell week occur year april
april volum trough covid impact upsid
extra week significantli reduc estim extra sell week
worth addit revenu
figur estim impact extra week
guid revenu
impli revenu declin took trend
provid us april may overlaid commentari
provid built slightli optimist recoveri
impli
appli overal direct model result breakdown
divis
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or affili manag co-manag public privat offer
compani receiv fee
deutsch bank and/or affili receiv compens compani provis invest
bank financi advisori servic within past year
deutsch bank and/or affili expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or affili receiv non-invest bank relat compens compani
within past year
compani client deutsch bank secur inc within past year time receiv
import disclosur requir non-u regul
